---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-014888"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2021-07-29T23:59:59+00:00"
generated_at: "2026-06-30T00:44:23.305622+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corcept Q2 revenue $91.6M; GAAP EPS $0.21; reiterates 2021 guidance $355-385M

## Summary
- Revenue $91.6M (+3.4% YoY); GAAP diluted EPS $0.21 vs $0.23; non-GAAP EPS $0.30 vs $0.32.
- Cash and investments $471.6M, +$16.8M from Q1; repurchased 1.4M shares for $30.8M.
- 2021 revenue guidance reaffirmed at $355-385M; CEO cites easing COVID restrictions driving growth.
- Phase 3 pivotal trial of relacorilant in platinum-resistant ovarian cancer expected to start Q1 2022.
- GRACE Phase 3 trial for relacorilant in Cushing's syndrome continues; NDA submission planned Q2 2023.

## SEC filing metadata
- accession: 0001628280-21-014888
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2021-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/0001628280-21-014888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828021014888/cort-20210729.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-014888
- JSON: https://secwatch.observer/filing/0001628280-21-014888.json
- Plain text: https://secwatch.observer/filing/0001628280-21-014888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.